02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
00:07 , Sep 5, 2018 |  BC Extra  |  Company News

Management tracks: Agios, Radius

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said David Schenkein will step down as CEO and become executive chairman, effective Feb. 1, 2019. He will succeed Chairman John Maraganore, who is also CEO at Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)....
19:24 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

FDA requests additional trial for Ampio's osteoarthritis therapy Ampion

Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) said FDA requested an additional randomized trial of Ampion to treat severe osteoarthritis (OA) of the knee prior to a BLA submission for the candidate. According to the company, FDA stated...
23:25 , Jan 9, 2018 |  BioCentury  |  Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
17:11 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

Ampio's Ampion meets in latest Phase III OA trial

Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) said Ampion met the primary endpoint in the Phase III AP-003-C trial to treat severe osteoarthritis (OA) of the knee. Ampio hopes to meet with FDA next quarter, after which the...
22:47 , Dec 14, 2017 |  BC Extra  |  Clinical News

Latest Phase III OA readout boosts Ampio shares

Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) added $0.58 (33%) to $2.33 on Thursday after reporting that Ampion met the primary endpoint in the Phase III AP-003-C trial to treat severe osteoarthritis of the knee. Ampio hopes to...
00:25 , Jun 21, 2017 |  BC Extra  |  Company News

Management tracks

Biogen Inc. (NASDAQ:BIIB) named Ginger Gregory EVP and chief human resources officer, effective July 17. She was chief human resources officer at Shire plc (LSE:SHP; NASDAQ:SHPG). Neurodegenerative, inflammation and cancer company Active Biotech AB (SSE:ACTI)...
23:42 , Jun 13, 2017 |  BC Extra  |  Company News

Management tracks

General Electric Co. (NYSE:GE) promoted Kieran Murphy to president and CEO of its GE Healthcare unit. He was president and CEO of GE Healthcare Life Sciences. Murphy succeeds John Flannery, who was named GE's CEO...
03:12 , Jun 9, 2017 |  BC Week In Review  |  Financial News

Ampio raises $6.6M in direct public offering

Inflammatory disease company Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) raised $6.6 million through the sale of 11 million units at $0.60 in a registered direct offering on June 7. Each unit comprises a share and a five-year...